Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maxigen BiotechTPE:1783 -0.25%87 EV-to-EBIT is 8.27 as of Aug. 23, 2026, which is 64% below its 10-year median of 22.89. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$58.09 (Significantly Undervalued). Among 475 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 80.63% on this metric.
The historical rank and industry rank for Maxigen Biotech's EV-to-EBIT or its related term are showing as below:
TPE:1783'
s EV-to-EBIT Range Over the Past 10 Years
Min: -5026.26 Med: 22.89 Max: 128.54
Current: 8.27
During the past 13 years, the highest EV-to-EBIT of Maxigen Biotech was 128.54. The lowest was -5026.26. And the median was 22.89.
TPE:1783's EV-to-EBIT is ranked better than 80.63% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.95
vs TPE:1783: 8.27
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Maxigen Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was NT$2,602.5 Mil.
Maxigen Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$329.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech EV-to-EBIT Related Terms
Maxigen Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's EV-to-EBIT falls into.
Maxigen Biotech's current Enterprise Value is NT$2,728.8 Mil.
Maxigen Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$329.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a EV-to-EBIT of 8.27 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Maxigen Biotech and its competitors. This is 64% below median its historical median of 22.89. According to the industry distribution chart, Maxigen Biotech ranks #92 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 19.4%.
Is Maxigen Biotech's EV-to-EBIT too high?
Maxigen Biotech's current EV-to-EBIT of 8.27 is 64% below median its 10-year median of 22.89. The Medical Devices & Instruments industry median EV-to-EBIT is 18.95. Maxigen Biotech's value of 8.27 is 56.4% below this industry median. Based on the distribution chart, Maxigen Biotech ranks #92 out of 475 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #92 out of 475 companies for EV-to-EBIT. This places Maxigen Biotech in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.95. Maxigen Biotech's value of 8.27 is 56.4% below this benchmark. While the company's 10-year median is 22.89 vs. the industry median of 18.95, Maxigen Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.95, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current EV-to-EBIT of 8.27 is 56.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current EV-to-EBIT is 8.27, which is 64% below median its own 10-year median of 22.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$58.09, compared to a current price of NT$40.40 — trading 30.5% below its estimated fair value. The current EV-to-EBIT is 8.27, which is 64% below median its 10-year median of 22.89 and 56.4% below the Medical Devices & Instruments industry median of 18.95. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current EV-to-EBIT is 8.27 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$40.40 is trading 30.5% below its estimated GF Value™ of NT$58.09.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
EV-to-EBIT: 8.27 (64% below median its 10-year median of 22.89)
GF Value™: NT$58.09 vs. price of NT$40.40 (30.5% below fair value)
Industry Position: 56.4% below the Medical Devices & Instruments median (#92 of 475)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
